Mondego Bio
- Company typePrivate
- Founded2025
- HeadquartersCantanhede, Portugal
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Mondego Bio does
Mondego Bio is a clinical-stage biotechnology company headquartered at Biocant Park in Cantanhede, Portugal, developing next-generation small-molecule immuno-oncology therapies. The company's lead program targets PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2), a negative regulator of the JAK-STAT pathway whose inhibition enhances IFNγ sensing and signaling to overcome immune resistance in solid tumors. Lead clinical candidate ZE00-0388 is an orally bioavailable, highly selective PTPN2 inhibitor that has demonstrated strong PTPN2/PTPN1 inhibitory activity, selectivity against other phosphatases, favorable preclinical safety, and complete and sustained tumor regression in MC38 colon cancer models when combined with anti-PD-1 therapy.
The company was incubated through Expert Systems' AI/ML-driven discovery platform in collaboration with Eilean Therapeutics (the origination science platform co-founded by OrbiMed and Torrey Pines) and Molsoft LLC. Mondego Bio integrates rational design, computational pharmacology, and medicinal chemistry to advance ZE00-0388 into a dual-track Phase 1 first-in-human study planned for H1 2026, covering both healthy volunteers and oncology patients. Manufacturing and clinical readiness are supported by an extended partnership with ChemDiv, giving the program cross-border infrastructure across Europe and the U.S.
Mondego Bio is pre-revenue and private, with no commercialized products. Its intended revenue model is pharmaceutical commercialization of PTPN2 inhibitors for oncology — both as monotherapy and in combination with immune checkpoint inhibitors — supplemented by potential licensing and royalty arrangements. The company completed Series A financing in September 2025 led by Biovance Capital with participation from OrbiMed and Torrey Pines Investment, which is funding the transition from discovery to clinical-stage operations.
Mondego Bio firmographics
Firmographics- Name
- Mondego Bio
- Legal name
- Mondego Bio
- Website
- https://mondegobio.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Mondego Bio industry classification
Industry- Product category
- Immuno-Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
- akta.pro secondary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Mondego Bio is headquartered
LocationHeadquarters
- HQ city
- Cantanhede
- HQ country
- Portugal
- HQ region
- Europe
Offices1 record
Markets served
Mondego Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Pharmaceutical Drug Development and Commercialization: Pre-revenue clinical-stage biotechnology company. Revenue model will be based on commercialization of PTPN2 inhibitor therapies for oncology. The company was incubated through Expert Systems AI/ML-driven discovery platform and is advancing ZE00-0388 into Phase 1 clinical trials in H1 2026.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Mondego Bio product offering
Product offeringCore offering
Mondego Bio is a clinical-stage biotechnology company developing best-in-class PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2) small-molecule inhibitors for cancer immunotherapy. Its lead clinical candidate ZE00-0388 is an AI-designed, highly selective PTPN2 inhibitor that enhances IFNγ sensing and signaling through the JAK-STAT pathway, intended as monotherapy or in combination with immune checkpoint inhibitors to overcome resistance in solid tumors.
Product overview
Mondego Bio is a clinical-stage biotechnology company developing next-generation small-molecule immuno-oncology therapies. The company is developing best-in-class PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2) inhibitors using AI/ML-driven molecular design. The primary product is ZE00-0388, a highly selective small-molecule PTPN2 inhibitor that enhances IFNγ sensing and signaling to improve cancer immunotherapy efficacy. The company integrates rational design, computational pharmacology, and medicinal chemistry expertise, incubated through the AI-driven discovery platform of Expert Systems in collaboration with Eilean Therapeutics and Molsoft LLC.
Differentiator
Problem solved
Functional benefit
Products and services
- ZE00-0388 (PTPN2 Inhibitor Clinical Candidate) AI-designed, highly selective small-molecule inhibitor of PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2) intended as a next-generation immuno-oncology therapy for solid tumors. Demonstrates strong PTPN2/PTPN1 inhibitory activity, outstanding selectivity against all other phosphatases, high oral bioavailability, and favorable safety profiles; induces tumor cell susceptibility to IFNγ and suppresses tumor growth. Intended for use as monotherapy and in combination with immune checkpoint inhibitors (e.g., anti-PD-1) for oncology patients.
Quantifiable outcome
- Complete and sustained tumor regression achieved in preclinical MC38 colon cancer models when ZE00-0388 combined with anti-mPD-1 therapy, persisting even after discontinuation of checkpoint inhibitor treatment
Companies that use Mondego Bio
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
Mondego Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature3 records
Mondego Bio partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and supporting.
- ChemDivcoreChemDiv announced an extension of its partnership with Mondego Bio to develop PTPN2 immuno-oncology programs. The collaboration involves drug discovery, scale-up manufacturing, and accelerating clinical readiness, supported by ChemDiv's and Mondego's facilities across Europe and the U.S.
- Expert Systems Inc.coreExpert Systems Inc., a leading drug discovery accelerator, announced the Series A funding and launch of Mondego Bio. Expert Systems provided AI/ML-driven molecular design platform that facilitated the discovery and development of Mondego Bio's PTPN2 inhibitors for immuno-oncology.
- Eilean TherapeuticscoreLead programs are based on research initially developed by Eilean Therapeutics, an AI/ML supported oncology platform co-founded by OrbiMed and Torrey Pines. Mondego Bio integrates rational design, computational pharmacology, and medicinal chemistry expertise to target intracellular regulators relevant to immune modulation and cancer biology.
- Molsoft LLCsupportingMondego Bio was incubated through the AI- and machine-learning-driven discovery platform of Expert Systems, in collaboration with Eilean Therapeutics and Molsoft LLC.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Mondego Bio competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Mondego Bio social profiles
Digital presenceMondego Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mondego Bio leadership team
Management profileNumber of profiles
Profiles9 records
Mondego Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mondego Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mondego Bio
What does Mondego Bio do?
Mondego Bio is a clinical-stage biotechnology company developing best-in-class PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2) small-molecule inhibitors for cancer immunotherapy. Its lead clinical candidate ZE00-0388 is an AI-designed, highly selective PTPN2 inhibitor that enhances IFNγ sensing and signaling through the JAK-STAT pathway, intended as monotherapy or in combination with immune checkpoint inhibitors to overcome resistance in solid tumors.
Is Mondego Bio a public or private company?
Mondego Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mondego Bio founded?
Mondego Bio was founded in 2025. It employs 1 to 10 people.
Where is Mondego Bio based?
Mondego Bio is headquartered in Cantanhede, Portugal, in the Europe region.
How does Mondego Bio make money?
One revenue line is on record: pharmaceutical Drug Development and Commercialization.
Does Mondego Bio have an API?
No public API is recorded for Mondego Bio.
What industry is Mondego Bio in?
Mondego Bio's product category is Immuno-Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.